Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

Background: This study compared glucose control with fast-acting insulin aspart (FiAsp) versus insulin aspart following moderate-intensity exercise (MIE) and high-intensity exercise (HIE) using a second-generation closed-loop (CL) system in people with type 1 diabetes.

Materials and Methods: This randomized crossover study compared FiAsp versus insulin aspart over four sessions during MIE and HIE with CL insulin delivery by the MiniMed™ Advanced hybrid CL system.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, men only.

Results: Sixteen adults (9 male; age 48 [37, 57] years; hemoglobin A1c (HbA1c) 7.0 [6.4, 7.2] %; duration diabetes 30 [17, 41] years) were recruited.

How the Study Was Run

In design terms this was a randomized and crossover study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

What Was Measured

The primary outcome was continuous glucose monitoring (CGM) time in range (TIR, 3.9-10.0 mM) for 24 h following exercise.

Topics PubMed links to this paper include Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin and Insulin Aspart.

Author keywords: Exercise, Fast-acting insulin aspart, Hybrid closed loop, Time in range and Type 1 diabetes.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart.

The publication is from 2022 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.